JP2007534725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007534725A5 JP2007534725A5 JP2007510038A JP2007510038A JP2007534725A5 JP 2007534725 A5 JP2007534725 A5 JP 2007534725A5 JP 2007510038 A JP2007510038 A JP 2007510038A JP 2007510038 A JP2007510038 A JP 2007510038A JP 2007534725 A5 JP2007534725 A5 JP 2007534725A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- agent
- seq
- polypeptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 108020004459 Small interfering RNA Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000004055 small Interfering RNA Substances 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 4
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 230000037182 bone density Effects 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 210000000963 osteoblast Anatomy 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000002805 bone matrix Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2004/004522 | 2004-04-27 | ||
| EP2004004522 | 2004-04-27 | ||
| PCT/EP2005/051914 WO2005103716A2 (en) | 2004-04-27 | 2005-04-27 | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007534725A JP2007534725A (ja) | 2007-11-29 |
| JP2007534725A5 true JP2007534725A5 (enExample) | 2008-06-05 |
| JP5128273B2 JP5128273B2 (ja) | 2013-01-23 |
Family
ID=34981963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510038A Expired - Fee Related JP5128273B2 (ja) | 2004-04-27 | 2005-04-27 | 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7615626B2 (enExample) |
| EP (3) | EP2214018B1 (enExample) |
| JP (1) | JP5128273B2 (enExample) |
| CA (1) | CA2562833A1 (enExample) |
| ES (1) | ES2427177T3 (enExample) |
| MX (1) | MXPA06012162A (enExample) |
| WO (1) | WO2005103716A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080193500A1 (en) * | 2007-02-14 | 2008-08-14 | Mckay William F | Effect of LMP-1 overexpression on large and small proteoglycans of the disc |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| MX2009013766A (es) * | 2007-06-20 | 2010-02-01 | Galapagos Nv | Objetivos moleculares y compuestos, y metodos para identificar los mismos, utiles en el tratamiento de enfermedades degenerativas de los huesos y las articulaciones. |
| US20100209436A1 (en) * | 2007-07-03 | 2010-08-19 | Andreas Reichert | Method for treating diseases related to mitochondrial dysfunction |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| DK2536285T3 (en) | 2010-02-18 | 2018-07-16 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use |
| KR20230044026A (ko) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| UA125636C2 (uk) | 2011-04-01 | 2022-05-11 | Іммуноджен, Інк. | Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат |
| JP6293147B2 (ja) | 2012-08-31 | 2018-03-14 | イミュノジェン， インコーポレイテッド | 葉酸受容体１の検出のための診断分析およびキット |
| WO2014129550A1 (ja) * | 2013-02-21 | 2014-08-28 | 国立大学法人熊本大学 | 骨分化誘導方法及び骨化促進・抑制分子のスクリーニング方法 |
| JP6247472B2 (ja) * | 2013-08-06 | 2017-12-13 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| LT3038650T (lt) | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
| JP6411778B2 (ja) * | 2014-06-06 | 2018-10-24 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| EP3349796A4 (en) | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES |
| JP6615589B2 (ja) * | 2015-11-13 | 2019-12-04 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| EP3491129A4 (en) * | 2016-07-29 | 2020-01-22 | Roger L. Kaspar | METHODS OF TREATING OSMIDROSIS |
| US11993590B2 (en) | 2016-12-04 | 2024-05-28 | 712 North Inc. | Pyranone compounds useful to modulate OMA1 protease |
| CN110049769A (zh) | 2016-12-04 | 2019-07-23 | 阿拉维·霍拉萨尼·默哈达姆·马塞尔·维克托 | 治疗与线粒体应激相关的疾病的方法 |
| WO2018138709A1 (en) * | 2017-01-30 | 2018-08-02 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
| WO2020117886A1 (en) * | 2018-12-07 | 2020-06-11 | Vtv Therapeutics Llc | Methods of inhibiting osteoclastogenesis and osteoclast activity |
| WO2021021631A1 (en) * | 2019-07-26 | 2021-02-04 | Ludwig Institute For Cancer Research Ltd | Immune cells with enhanced cytotoxicity and methods of use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JPH04365487A (ja) * | 1990-04-11 | 1992-12-17 | Consortium Elektrochem Ind Gmbh | 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳 |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| JPH11335398A (ja) * | 1998-05-22 | 1999-12-07 | Hoechst Marion Roussel Kk | 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬 |
| US20020192209A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| US6056559A (en) * | 1997-10-01 | 2000-05-02 | Berg Technology, Inc. | Punched sheet coax header |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| WO2001046436A1 (fr) * | 1999-12-22 | 2001-06-28 | Tanabe Seiyaku Co., Ltd. | Nouvelles phosphodiesterases et leurs genes |
| US20030108926A1 (en) * | 2000-03-15 | 2003-06-12 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| GB0204227D0 (en) * | 2002-02-22 | 2002-04-10 | Pfizer Ltd | Modulation of pde11a activity |
| US20060121550A1 (en) * | 2000-11-01 | 2006-06-08 | Burslem Martyn F | Modulation of PDE11A activity |
| EP1211313A3 (en) * | 2000-11-01 | 2003-04-23 | Pfizer Limited | Modulation of PDE11A activity |
| US6828473B2 (en) * | 2000-11-01 | 2004-12-07 | Pfizer Inc. | Modulation of PDE11A activity |
| US20030104410A1 (en) * | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
| WO2002092000A2 (en) * | 2001-05-11 | 2002-11-21 | Genome Therapeutics Corporation | Hbm variants that modulate bone mass and lipid levels |
| EP1446757A2 (en) * | 2001-05-30 | 2004-08-18 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| AU2002355857A1 (en) * | 2001-08-03 | 2003-02-17 | Gene Logic, Inc. | Gene associated with bone disorders |
| US20030198627A1 (en) * | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| WO2003025176A2 (fr) * | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
| EP1546727A2 (en) * | 2002-09-24 | 2005-06-29 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US20050266409A1 (en) * | 2003-02-04 | 2005-12-01 | Wyeth | Compositions and methods for diagnosing, preventing, and treating cancers |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| ATE494550T1 (de) * | 2003-04-25 | 2011-01-15 | Takeda Pharmaceutical | Neues screening-verfahren |
| US20080038247A1 (en) * | 2003-05-05 | 2008-02-14 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39) |
| JP2007528734A (ja) * | 2004-03-12 | 2007-10-18 | エクセリクシス， インク． | Ｉｇｆｒ経路のモディファイヤーとしてのｐｄｅ及び使用方法 |
-
2005
- 2005-04-27 MX MXPA06012162A patent/MXPA06012162A/es active IP Right Grant
- 2005-04-27 EP EP10158238.5A patent/EP2214018B1/en not_active Expired - Lifetime
- 2005-04-27 EP EP05747396A patent/EP1747462A2/en not_active Withdrawn
- 2005-04-27 CA CA002562833A patent/CA2562833A1/en not_active Abandoned
- 2005-04-27 WO PCT/EP2005/051914 patent/WO2005103716A2/en not_active Ceased
- 2005-04-27 ES ES10158238T patent/ES2427177T3/es not_active Expired - Lifetime
- 2005-04-27 JP JP2007510038A patent/JP5128273B2/ja not_active Expired - Fee Related
- 2005-04-27 EP EP10174527A patent/EP2259063B1/en not_active Expired - Lifetime
-
2006
- 2006-10-23 US US11/551,744 patent/US7615626B2/en not_active Expired - Fee Related
-
2009
- 2009-10-30 US US12/609,335 patent/US8318137B2/en not_active Expired - Fee Related
-
2012
- 2012-10-30 US US13/664,027 patent/US8883425B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007534725A5 (enExample) | ||
| JP2008516593A5 (enExample) | ||
| AU2023237051B2 (en) | Oligonucleotide probes and uses thereof | |
| JP6912538B2 (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| JP2008503712A5 (enExample) | ||
| US8883425B2 (en) | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts | |
| JP6437467B2 (ja) | 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 | |
| ES2679798T3 (es) | Método para proporcionar linfocitos T específicos de tumor | |
| JP2010538244A (ja) | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 | |
| US20160003808A1 (en) | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition | |
| KR102534098B1 (ko) | 항암제 내성 진단 또는 치료용 조성물 | |
| EP2868747B1 (en) | Aptamer for periostin and anti-cancer composition including same | |
| JP2008502355A5 (enExample) | ||
| JP6895175B2 (ja) | エクソソーム分泌阻害剤 | |
| JP2012517822A (ja) | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 | |
| EP2210112B1 (en) | Diagnostic methods for hiv infection | |
| WO2005121778B1 (en) | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases | |
| JP2007533989A5 (enExample) | ||
| JP2016518812A (ja) | 線維症治療において有用な分子標的及び前記標的のインヒビター | |
| CN119301256A (zh) | 外囊泡融合蛋白及其应用 | |
| JP2016053575A (ja) | 変形性関節症の治療のための方法及び手段 | |
| JP2005503123A5 (enExample) | ||
| HK40007814A (en) | Oligonucleotide probes and uses thereof |